3rd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5813 (114th), S. 1800 (114th), H.R. 3049 (114th)

Medicare/Medicaid MMM

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES

Bills named: H.R. 592 (114th), S. 314 (114th)

Pharmacy PHA

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

LobbyistCovered position, as disclosed
NICHOLAS GENTILE —
JOSEPH M HILL —
JILLANNE SCHULTE —
CHRISTOPHER J TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); SENATE

Bills named: S. 524 (114th), S. 2700 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.